Korean Stem Cells Allow Artist to Paint Again

ROCKVILLE, Md., March 31 /PRNewswire/ -- John Lawson Cullison, Jr., an artist known for his work in the genre of visionary realism or "new age art," lost his ability to paint due to the effects of arthritis. This incurable condition is due to the degeneration in cartilage tissue and symptoms include: pain, tenderness in the joints, stiffness, loss of flexibility, bone spurs and severe swelling. Pain management and joint replacement surgery are the typical means to treating this condition. Cullison was taking prescription pain medication for over 15 years when he finally decided to seek treatment that was unavailable in the United States.

RNL Bio, a South Korean adult stem cell therapy company, developed a method to take one's own stem cells from fat tissue and make identical copies that have no genetic modifications and no cancer risks so that high doses of stem cells can be administered back into the body. The stem cells that come from fat tissue can easily form new tissues. Given that characteristic, the stem cells have the capacity to treat any tissue degenerative disease which includes, Parkinson's Disease, Spinal Cord Injury, Renal Failure, among many. When Cullison heard of the treatment, he sent a small fat sample to RNL Bio, where the cells would be manufactured under the strictest safety and quality conditions.

February 2009, Cullison made the trip to Seoul, South Korea where he was escorted by RNL staff to The Sunrise Regenerative Medical Center, their stem cell hospital in Yanji, China to receive intravenous and local injections of his own stem cells. When asked about his decision to seek this new and developing treatment, he said, "I had more faith in that [the fact that RNL was using my own stem cells] because I knew that I would be receiving the material that genetically was supposed to be in me.".

A week after his injection, Cullison began to see small improvements and after two weeks, he no longer needed his cane to walk. He noticed that his joints were feeling better, his vision was improving to the point that his glasses were outdated, his eyes were getting bluer (eye pigmentation is often an indicator of good health) and his legs were getting stronger. "This is major improvement and it's only been 2 weeks! Six months from now, I'll be doing back-flips!" Only three weeks post treatment, Cullison reported that he was no longer taking any medication and back to painting his pictures.

President and CEO of RNL Bio, Dr. Jeong Chan Ra said, "John Cullison arrived in Korea as an old man. He is returning to his home, an adolescent". After witnessing the remarkable improvement of Cullison as well as patients being treated with RNL stem cells, Ra is committed to making RNL stem cell therapy an accessible and affordable treatment, globally.

About RNL Bio

RNL Bio is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis. RNL is a publically traded company on the Korean Stock Exchange (Code 003190) and plans to expand its operations throughout the world. For questions regarding the press conference or receiving stem cell therapy, please contact, Jin Han Hong, at hongjh@rnl.co.kr

SOURCE RNL Bio